Results 171 to 180 of about 22,744 (213)

Invited Commentary: Ten-Year Outcome of a Randomized Trial: Cytoreduction and HIPEC with Mitomycin C Versus Oxaliplatin for Appendiceal Neoplasm with Peritoneal Dissemination, by Levine et al. [PDF]

H. Richard Alexander
openalex   +1 more source

Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer

, 2010
Linn Woelber, Sung Hoo Jung, Christine zu Eulenburg, Volkmar Mueller, J. Schwarz, Fritz Jaenicke, Sven� Mahner   +6 more
openalex   +2 more sources

Cell migration, chimerism, and graft acceptance [PDF]

, 1992
A.J Demetris, Armstrong, Arnaud-Battandier, Billingham, Billingham, C Ricordi, Calne, Cranston, Davies, Demetris, Demetris, Faustman, Fung, Gjertson, Hart, Ildstad, Iwaki, Kashiwagi, Kashiwagi, Lechler, M Trucco, Markus, Medawar, Monaco, Murase, Murase, Murase, Murase, N Murase, Porter, Prop, Ramsey, Ricordi, S Ildstad, Selby, Singh, Slavin, Starzl, Starzl, Starzl, Steinman, Steinmuller, T.E Starzl, Talmage, Webb, Wilson, Woodruff, Woodruff   +47 more
core   +1 more source

Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients

, 2018
Young-Jae Lee, Yong‐Man Kim, Phill-Seung Jung, Jong Jin Lee, Jeong Kon Kim, Young‐Tak Kim, Joo-Hyun Nam   +6 more
openalex   +1 more source

Prognostic and predictive value of supradiaphragmatic lymph node involvement detected by 18F-FDG PET/CT in advanced ovarian cancer: a systematic review and meta-analysis. [PDF]

Arch Gynecol Obstet
Braun C, Peikert J, Brambs C.
europepmc   +1 more source

Efficacy and safety of oxaliplatin-based hyperthermic intraperitoneal chemotherapy with secondary cytoreduction for platinum resistant recurrent ovarian cancer: A single-center retrospective cohort study

Hua-Hsi Wu, Peng-Hui Wang, Yi‐Jen Chen, Wei‐Ting Chao   +3 more
openalex   +1 more source

Cytoreductive Surgery in Ovarian Cancer: Should the New Optimal Threshold Be 2.5 mm? [PDF]

J Clin Med
Grigorie TR, Potlog G, Verdea C, Chiriac TD, Popescu GA, Minca DG, Costea RV, Brebu D, Alexandrescu ST.   +8 more
europepmc   +1 more source

Case Report: Biweekly TAS-102 and bevacizumab as maintenance therapy for recurrent and metastatic pseudomyxoma peritonei following palliative cytoreduction. [PDF]

Front Oncol
Wang B, Wang Y, Zhao D, Zhang H, Liu Q, Yu G, Jiao J.   +6 more
europepmc   +1 more source

Feasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib

, 2015
Shih-Chun Chang, Chien‐Hung Liao, Shang‐Yu Wang, Chun‐Yi Tsai, Kun‐Chun Chiang, Chi‐Tung Cheng, Ta‐Sen Yeh, Yen‐Yang Chen, Ming‐Chun Ma, Chien-Ting Liu, Chun‐Nan Yeh   +10 more
openalex   +1 more source

Management of Suspected Stage IVA Endometrial Cancer With Rectosigmoid Involvement Using Neoadjuvant Chemotherapy and Interval Surgery. [PDF]

Cureus
Gunasagran Y, Lim K.
europepmc   +1 more source